Welcome to our dedicated page for Allarity Therapeutics news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity Therapeutics stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. Founded in 2012, this innovative company is committed to unlocking the potential of new oncology products and rescuing failed drugs. Through its proprietary Drug Response Predictor (DRP®) technology, Allarity enhances patient selection and improves clinical outcomes in oncology.
Allarity boasts an impressive pipeline of in-licensed oncology therapeutics targeting difficult-to-treat cancers. Its lead product, stenoparib, a novel PARP/Tankyrase dual inhibitor, is currently being tested in advanced ovarian cancer patients. The DRP® companion diagnostic plays a crucial role in identifying patients who will benefit most from stenoparib, thereby increasing therapeutic efficacy and improving patient outcomes.
Recent achievements include significant advancements in their clinical trials, strategic financial restructurings, and compliance with Nasdaq listing requirements. The company's strategic pivot focuses on accelerating stenoparib's development, driven by promising Phase 2 trial data showing tumor shrinkage and long-term disease stability in heavily pre-treated ovarian cancer patients.
Allarity operates with research facilities in Denmark and a headquarters in the United States, underscoring its commitment to addressing significant unmet medical needs in cancer treatment. The company maintains an active presence in the clinical-stage pharmaceutical landscape, continually striving to develop novel personalized cancer treatments.
Visit www.allarity.com for more information and follow Allarity on LinkedIn and Twitter.
FAQ
What is the current stock price of Allarity Therapeutics (ALLR)?
The current stock price of Allarity Therapeutics (ALLR) is $1.41 as of January 29, 2025.
What is the market cap of Allarity Therapeutics (ALLR)?
The market cap of Allarity Therapeutics (ALLR) is approximately 5.8M.
What does Allarity Therapeutics specialize in?
Allarity Therapeutics specializes in developing personalized cancer treatments using their Drug Response Predictor (DRP®) technology to enhance patient selection and improve clinical outcomes.
What is DRP® technology?
The Drug Response Predictor (DRP®) is a companion diagnostic tool that screens patients based on their cancer's gene expression signature to identify those most likely to benefit from specific oncology drugs.
What are the main products in Allarity Therapeutics’ pipeline?
Allarity Therapeutics' pipeline includes stenoparib, a novel PARP/Tankyrase dual inhibitor for advanced ovarian cancer, as well as other formulations like Dovitinib and Ixempra.
Where is Allarity Therapeutics headquartered?
Allarity Therapeutics is headquartered in the United States with a research facility in Denmark.
How has Allarity Therapeutics recently improved its financial standing?
Allarity has taken steps to regain compliance with Nasdaq listing requirements, including restructuring its financials, raising new equity, and reducing costs, resulting in a strengthened financial position.
What recent achievements has Allarity Therapeutics announced?
Recent achievements include significant clinical trial progress with stenoparib, achieving Nasdaq compliance, and strategic financial restructuring to support further development.
How does stenoparib work?
Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, which helps in blocking Wnt pathway activation and shows promise as a therapeutic for advanced ovarian cancer.
What are the benefits of using the DRP® companion diagnostic?
By using the DRP® companion diagnostic, Allarity can select patients with a high likelihood of benefiting from specific drugs, thus increasing therapeutic efficacy and improving patient outcomes.
Has Allarity Therapeutics regained compliance with Nasdaq’s listing requirements?
Yes, Allarity Therapeutics has regained compliance with Nasdaq’s minimum bid price and equity requirements, allowing continued listing and trading on Nasdaq.
What is the significance of the strategic pivot announced by Allarity Therapeutics?
The strategic pivot focuses on accelerating the development of stenoparib, driven by promising clinical data, and aims to address unmet medical needs in advanced ovarian cancer, potentially leading to regulatory approval.